National Institute of Allergy and Infectious Diseases (NIAID)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Institute of Allergy and Infectious Diseases (NIAID) sits in the top decile of US sponsors by registered trial count (#5 of 15,742 sponsors by registered trial count).
National Institute of Allergy and Infectious Diseases (NIAID): 2,006 sponsored US clinical trials, 155 recruiting.
National Institute of Allergy and Infectious Diseases (NIAID) sponsors 2,006 registered US clinical trials on ClinicalTrials.gov, 155 of them currently recruiting, and 1,642 completed. 177 of these trials are in Phase 3-4 (later-stage) and 1,291 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is HIV Infections, with 195 trials.
Top-decile sponsor footprint
National Institute of Allergy and Infectious Diseases (NIAID) ranks in the top decile of sponsors by registered trial count (#5 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,642 of 1,802 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
2,006 total, page 22 of 41
A/H5N1 Vaccine in Healthy Children Aged 2-9 Years
NCT00133536
Safety of and Immune Response to the Experimental Preventive HIV Vaccine, EP HIV-1090, in Healthy, HIV-1 Uninfected Adults
NCT00141024
Safety, Tolerability and Immune Response to LC002, an Experimental Therapeutic Vaccine, in Adults Receiving HAART
NCT00270205
Safety and Immune Response to a Prime-Boost Vaccination Schedule in HIV-infected Patients
NCT00270465
Studies of Disorders in Antibody Production and Related Primary Immunodeficiency States
NCT00266513
STA-5326 Meslylate to Treat Gut Inflammation Associated With Common Variable Immunodeficiency
NCT00263237
Pentavalent DTaP-Hep B-IPV
NCT00133445
Immune Response to Varicella Vaccination in Children With Atopic Dermatitis
NCT00406081
Omalizumab to Treat Hyper-IgE (Job's) Syndrome
NCT00260702
Immune Response to Mycobacterium Tuberculosis Infection
NCT00257907
The Immunological and Blood Effects of STA-5326 Mesylate on Patients With Crohn's Disease
NCT00250198
Immunogenicity and Safety of Different Doses of Fluzone® Influenza
NCT00253734
Safety, Effectiveness, and Tolerability of Ezetimibe Combined With Statins for the Treatment of High Cholesterol in HIV Infected Adults
NCT00099684
Chart Review of Antivirals for Influenza in Infants
NCT00311701
Open Label Evaluation of H5N1 Vaccine at Vaccine Manufacturing Facilities
NCT00311649
T-cell Response-Flu Risk in Older Adults
NCT00138398
RSV Disease in the Elderly
NCT00246480
Cell-Mediated Immune Responses to Influenza A/H5N1 Vaccine
NCT00311727
H5 Booster After a Two Dose Schedule
NCT00240968
ACAM 3000 MVA at Harvard Medical School
NCT00133575
Revaccination With Subunit Influenza A/Vietnam/1203/2004 (H5N1) Vaccine
NCT00240903
Differences in Blood Levels of Lopinavir/Ritonavir in HIV Infected Men and Women
NCT00102986
Monoclonal Antibody for Treatment of Inhalation Anthrax
NCT00138411
Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant
NCT00135694
Inactivated Influenza A/H5N1 Vaccine in the Elderly
NCT00230750
Immune Responses to Two Dose Varivax +/- MMR-II
NCT00258726
Effect of Intermittent Aldesleukin Treatment With or Without Anti-HIV Drugs in HIV Infected People
NCT00110812
Autoimmunity-blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes
NCT00129259
A Phase I Safety and Immunogenicity Study of Mix and Match of Licensed Flu Vaccine and Flumist
NCT00231907
HVTN Protocol 204 - A Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA016-00-VP, Followed by a Multiclade Recombinant Adenoviral Vector HIV-1 Vaccine Boost, VRCHIVADV014-00-VP, in HIV-1 Uninfected Adult Participants
NCT00125970
Comparison of Delivery Routes of Flu Vaccine in Adults
NCT00170547
Analysis of Lyme Disease Lesions
NCT00132327
Comparison of Inactivated and Live, Attenuated Influenza Vaccine in Children 5-9 Years of Age-Year 3 Amendment
NCT00138385
Herpevac Neonatal Substudy
NCT00138320
Safety of and Immune Response to a Tick-Borne Encephalitis Vaccine (LGT(TP21)/DEN4) in Healthy Adults
NCT00118924
H5N1 Vaccine Intramuscular Versus Intradermal in Healthy Adults
NCT00310206
Controlling Acute or Early HIV Infection With Antiretroviral Drugs, Without a Candidate Vaccine.As Reported Previously, the Candidate Vaccie Was Not Provided by the Maufacturer as Promised
NCT00238459
Comparison of Cathelicidin Expression in Skin and Saliva in Patients With Atopic Dermatitis and Psoriasis
NCT00407979
Safety of and Immune Response to a Bird Flu Virus Vaccine (H9N2) in Healthy Adults (Study A)
NCT00110279
Role of Antimicrobial Peptides in Host Defense Against Vaccinia Virus
NCT00407069
Immune System Suppression With Alemtuzumab and Tacrolimus in Liver Transplantation Patients
NCT00105235
SCOT Scleroderma Treatment Alternative Registry (STAR Registry)
NCT00860548
Young Adult Influenza Vaccine Immunogenicity Substudy
NCT00170508
Scleroderma: Cyclophosphamide or Transplantation
NCT00114530
Adjuvant Cytokine Therapy to Treat Pulmonary Mycobacterium Avium Complex Infection
NCT00111397
Amphotericin Alone or in Combination With Fluconazole for AIDS-Associated Meningitis
NCT00145249
Effect of Tenofovir Disoproxil Fumarate on Lipid Levels in HIV Infected Adults on Stable Anti-HIV Drug Therapy
NCT00109603
Atorvastatin (Lipitor) Therapy in Patients With Clinically Isolated Syndrome (CIS) at Risk for Multiple Sclerosis
NCT00094172
AMA1-C1/Alhydrogel + CpG 7909 for Malaria
NCT00344539
"Prime-Boost" Vaccine Schedule for Prevention of HIV Infection
NCT00109629
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 858 |
| Phase 2 | 433 |
| Phase 3 | 123 |
| Phase 4 | 54 |
Therapeutic Areas
What is open in the National Institute of Allergy and Infectious Diseases (NIAID) pipeline
155 recruiting of 2,006 indexed (8% open); 1,642 completed (82%).
Phase mix: 177 late (III/IV) vs 1,291 early (I/II) (early-phase heavy).
Top condition: HIV Infections (195 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
National Institute of Allergy and Infectious Diseases (NIAID): open-pipeline peers nationwide
Peers matched on 2,006 registered trials and 8% open enrollment, not the therapeutic-area sidebar.
National Institute of Allergy and Infectious Diseases (NIAID) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 2,006 trials (± recruiting share)
- Massachusetts General Hospital · 2,032 trials · 17% recruiting
- Memorial Sloan Kettering Cancer Center · 1,884 trials · 17% recruiting
- Pfizer · 1,845 trials · 6% recruiting
- Stanford University · 1,744 trials · 15% recruiting
Sponsors near 8% open enrollment (± trial volume)
- Alumis · 8% recruiting · 13 trials
- Andrei Iagaru · 8% recruiting · 13 trials
- BioXcel Therapeutics · 8% recruiting · 13 trials
- Corporal Michael J. Crescenz VA Medical Center · 8% recruiting · 13 trials
Related
What to do with this National Institute of Allergy and Infectious Diseases (NIAID) page
2,006 registered trials is a research-attention snapshot, not an endorsement of National Institute of Allergy and Infectious Diseases (NIAID) or any single study.
- 155 of National Institute of Allergy and Infectious Diseases (NIAID)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- HIV Infections is the condition National Institute of Allergy and Infectious Diseases (NIAID) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See HIV Infections trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. National Institute of Allergy and Infectious Diseases (NIAID) pipeline card: 2,006 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.